Diligence memo · auto-generated · as of July 2, 2026
Sancilio & Company, Inc.
Sancilio & Company, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Sancilio & Company, Inc. operates in Pharmaceuticals, based in RIVIERA BEACH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sancilio & Company, Inc. has raised $22M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2014-05-20.
Most recent recorded round closed around 2014-05-20.
Valuation (modeled)modeled
Provath models Sancilio & Company, Inc. at approximately $680M (range $42M–$2.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series B Pharmaceuticals companies in 2013–2015 (42 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 12.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 10.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 68% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: Lipocine Inc., CARDEAS PHARMA Corp, CoLucid Pharmaceuticals, Inc., Emisphere Technologies Inc, Vasculox, Inc..
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.